Incidence and risk of CHD in symptomatic menopausal and control cohorts.

Incidence and risk of CHD in symptomatic menopausal and control cohorts.</p

Subgroup analyses of the risk of CHD in symptomatic menopausal and control cohorts.

Subgroup analyses of the risk of CHD in symptomatic menopausal and control cohorts.</p

Baseline characteristics of symptomatic menopausal and control cohorts.

Baseline characteristics of symptomatic menopausal and control cohorts.</p

Cumulative incidence of CHD in symptomatic menopausal and control cohorts.

Cumulative incidence of CHD in symptomatic menopausal and control cohorts.</p

Flowchart of selection of patients with menopausal symptoms from the NHIRD and selection of controls from age-, CCI-score-, index-date-, and propensity-score-matched asymptomatic women.

Flowchart of selection of patients with menopausal symptoms from the NHIRD and selection of controls from age-, CCI-score-, index-date-, and propensity-score-matched asymptomatic women.</p

HT and the Risk of CHD.

HT and the Risk of CHD.</p

Additional file 2: of Strong association between metabolically-abnormal obesity and gallstone disease in adults under 50 years

Table S2. Risk of gallstones in multivariate analyses. (DOCX 16 kb

Association between smoking and glycemic control in men with newly diagnosed type 2 diabetes: a retrospective matched cohort study

Longitudinal data on the association between smoking and glycemic control in men with newly diagnosed type 2 diabetes (T2DM) is scarce. Therefore, this study aimed to examine the extent of the association between smoking and glycemic control in this population. The retrospective cohort study identified 3044 eligible men with T2DM in a medical centre in Taiwan between 2002 and 2017. Smokers (n = 757) were matched 1:1 with non-smokers using propensity score-matching. All of them were followed for one year. Glycated haemoglobin (HbA1c) levels were measured at 0, 3, 6, 9, and 12 months after enrolment. Generalised estimating equations were used to assess smoking status-by-time interaction to determine the difference in HbA1c reduction between the two cohorts. All analyses were performed in 2020. The estimated maximal difference in HbA1c reduction between smokers and non-smokers was 0.33% (95% CI, 0.05–0.62%) at 3 months of follow-up. For patients with body mass index (BMI) 2, the difference in HbA1c reduction between smokers and non-smokers was much larger (0.74%, 95% CI, 0.35–1.14%) than in those with a higher BMI. Our findings show that smoking was independently associated with unfavourable glycemic control among men with newly diagnosed T2DM, and such a detrimental association could be stronger in men with a lower BMI.</p

Additional file 1: of Strong association between metabolically-abnormal obesity and gallstone disease in adults under 50 years

Table S1. Baseline characteristics of participants according to participants < 50 and ≥ 50 years. (DOCX 16 kb

Incidence and hazard ratios of diabetes mellitus for appendectomy patients compared with non-appendectomy cohort by demographic characteristics and comorbidities.

Incidence and hazard ratios of diabetes mellitus for appendectomy patients compared with non-appendectomy cohort by demographic characteristics and comorbidities.</p